The histone deacetylase inhibitor sodium valproate causes limited transcriptional change in mouse embryonic stem cells but selectively overrides Polycomb-mediated Hoxb silencing

Epigenetics and Chromatin

Volumn 6, Issue 1, 2013, Pages

  Boudadi, Elsa ^a   Stower, Hannah ^a   Halsall, John A ^a   Rutledge, Charlotte E ^a   Leeb, Martin ^b   Wutz, Anton ^b   O'Neill, Laura P ^a   Nightingale, Karl P ^a   Turner, Bryan M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Histone deacetylase; Histone modification; Hoxb genes; Microarray expression analysis; Mouse embryonic stem cells; Polycomb repression; Retinoic acid; Transcriptional activation; Valproic acid

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; POLYCOMB GROUP PROTEIN; RETINOIC ACID; VALPROIC ACID;

ARTICLE; CELL DIFFERENTIATION; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; BURKITT LYMPHOMA; CELL LINE, TUMOR; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876785540     PISSN: None     EISSN: 17568935     Source Type: Journal    
DOI: 10.1186/1756-8935-6-11     Document Type: Article

References (56)

1. Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. Nightingale KP, Gendreizig S, White DA, Bradbury C, Hollfelder F, Turner BM, J Biol Chem 2007 282 4408 4416 17166833 (Pubitemid 47100929)
2. Histone deacetylase inhibitors: potential in cancer therapy. Marks PA, Xu WS, J Cell Biochem 2009 107 600 608 10.1002/jcb.22185 19459166
3. FDA oncology drug product approvals in 2009. StatBite, J Natl Cancer Inst 2009 102 4 219
4. Histone deacetylase inhibitors as anti-neoplastic agents. Batty N, Malouf GG, Issa JP, Cancer Lett 2009 280 192 200 10.1016/j.canlet.2009.03.013 19345475
5. Histone deacetylases and epigenetic therapies of hematological malignancies. Mercurio C, Minucci S, Pelicci PG, Pharmacol Res 2010 62 18 34 10.1016/j.phrs.2010.02.010 20219679
6. Histone deacetylase inhibitors: molecular mechanisms of action. Xu WS, Parmigiani RB, Marks PA, Oncogene 2007 26 5541 5552 10.1038/sj.onc.1210620 17694093 (Pubitemid 47255934)
7. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Haberland M, Montgomery RL, Olson EN, Nat Rev Genet 2009 10 32 42 10.1038/nrg2485 19065135
8. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Haigis MC, Guarente LP, Genes Dev 2006 20 2913 2921 10.1101/gad.1467506 17079682 (Pubitemid 44771725)
9. Histone modifying enzymes: structures, mechanisms, and specificities. Marmorstein R, Trievel RC, Biochim Biophys Acta 2009 1789 58 68 10.1016/j.bbagrm.2008.07.009 18722564
10. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Qiu Y, Zhao Y, Becker M, John S, Parekh BS, Huang S, Hendarwanto A, Martinez ED, Chen Y, Lu H, Adkins NL, Stavreva DA, Wiench M, Georgel PT, Schiltz RL, Hager GL, Mol Cell 2006 22 669 679 10.1016/j.molcel.2006.04.019 16762839 (Pubitemid 43817601)
11. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS, J Biol Chem 2001 276 36734 36741 10.1074/jbc.M101287200 11473107
12. Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Gerstner T, Bell N, Konig S, Expert Opin Pharmacother 2008 9 285 292 10.1517/14656566.9.2.285 18201150 (Pubitemid 351233735)
13. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA, Cancer Treat Rev 2008 34 206 222 10.1016/j.ctrv.2007.11.003 18226465
14. Teratogenicity of sodium valproate. Alsdorf R, Wyszynski DF, Expert Opin Drug Saf 2005 4 345 353 10.1517/14740338.4.2.345 15794725 (Pubitemid 40867344)
15. Teratogenicity of antiepileptic medications. Kluger BM, Meador KJ, Semin Neurol 2008 28 328 335 10.1055/s-2008-1079337 18777479
16. Verification of the fetal valproate syndrome phenotype. Ardinger HH, Atkin JF, Blackston RD, Elsas LJ, Clarren SK, Livingstone S, Flannery DB, Pellock JM, Harrod MJ, Lammer EJ, Am J Med Genet 1988 29 171 185 10.1002/ajmg.1320290123 3125743 (Pubitemid 18036040)
17. Valproic acid-induced skeletal malformations: associated gene expression cascades. Massa V, Cabrera RM, Menegola E, Giavini E, Finnell RH, Pharmacogenet Genomics 2005 15 787 800 10.1097/01.fpc.0000170914.11898.3a 16220111 (Pubitemid 41531728)
18. Valproic Acid Downregulates RBP4 and Elicits Hypervitaminosis A-Teratogenesis-A Kinetic Analysis on Retinol/Retinoic Acid Homeostatic System. Chuang CM, Chang CH, Wang HE, Chen KC, Peng CC, Hsieh CL, Peng RY, PLoS One 2012 7 43692 10.1371/journal.pone.0043692 23028466
19. Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects. Tung EW, Winn LM, Mol Pharmacol 2011 80 979 987 10.1124/mol.111.072314 21868484
20. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Rada-Iglesias A, Enroth S, Ameur A, Koch CM, Clelland GK, Respuela-Alonso P, Wilcox S, Dovey OM, Ellis PD, Langford CF, Dunham I, Komorowski J, Wadelius C, Genome Res 2007 17 708 719 10.1101/gr.5540007 17567991 (Pubitemid 46919708)
21. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K, Cell 2009 138 1019 1031 10.1016/j.cell.2009.06.049 19698979
22. Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors. Halsall J, Gupta V, O'Neill LP, Turner BM, Nightingale KP, PLoS One 2012 7 33453 10.1371/journal.pone.0033453 22479401
23. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Van Lint C, Emiliani S, Verdin E, Gene Expr 1996 5 245 253 8723390
24. An integrated encyclopedia of DNA elements in the human genome. Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, Epstein CB, Frietze S, Harrow J, Kaul R, Khatun J, Lajoie BR, Landt SG, Lee BK, Pauli F, Rosenbloom KR, Sabo P, Safi A, Sanyal A, Shoresh N, Simon JM, Song L, Trinklein ND, Altshuler RC, Birney E, Brown JB, Cheng C, Djebali S, Dong X, Ernst J, Nature 2012 2012 489 57 74
25. Regulation of chromatin by histone modifications. Bannister AJ, Kouzarides T, Cell Res 2011 21 381 395 10.1038/cr.2011.22 21321607
26. Histone modification: cause or cog? Henikoff S, Shilatifard A, Trends Genet 2011 27 389 396 10.1016/j.tig.2011.06.006 21764166
27. The adjustable nucleosome: an epigenetic signaling module. Turner BM, Trends Genet 2012 28 436 444 10.1016/j.tig.2012.04.003 22633123
28. A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Faiella A, Wernig M, Consalez GG, Hostick U, Hofmann C, Hustert E, Boncinelli E, Balling R, Nadeau JH, Hum Mol Genet 2000 9 227 236 10.1093/hmg/9.2.227 10607833 (Pubitemid 30052746)
29. The pathophysiology of HOX genes and their role in cancer. Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL, Lappin TR, J Pathol 2005 205 154 171 10.1002/path.1710 15643670 (Pubitemid 40227988)
30. Coordinate expression of the murine Hox-5 complex homoeobox-containing genes during limb pattern formation. Dolle P, Izpisua-Belmonte JC, Falkenstein H, Renucci A, Duboule D, Nature 1989 342 767 772 10.1038/342767a0 2574828 (Pubitemid 20023809)
31. Chromatin decondensation and nuclear reorganization of the HoxB locus upon induction of transcription. Chambeyron S, Bickmore WA, Genes Dev 2004 18 1119 1130 10.1101/gad.292104 15155579 (Pubitemid 38669033)
32. Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. VerMilyea MD, O'Neill LP, Turner BM, PLoS One 2009 4 6086 10.1371/journal.pone.0006086 19564914
33. Verification and initial annotation of the NIA mouse 15K cDNA clone set. Kargul GJ, Dudekula DB, Qian Y, Lim MK, Jaradat SA, Tanaka TS, Carter MG, Ko MS, Nat Genet 2001 28 17 18 11326268 (Pubitemid 32405809)
34. Dosage compensation in the mouse balances up-regulation and silencing of X-linked genes. Lin H, Gupta V, Vermilyea MD, Falciani F, Lee JT, O'Neill LP, Turner BM, PLoS Biol 2007 5 326 10.1371/journal.pbio.0050326 18076287 (Pubitemid 351181195)
35. Relative overexpression of X-linked genes in mouse embryonic stem cells is consistent with Ohno's hypothesis. Lin H, Halsall JA, Antczak P, O'Neill LP, Falciani F, Turner BM, Nat Genet 2011 43 1169 1170 author reply 1171-1162 10.1038/ng.992 22120049
36. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, Cheng T, Kho Y, Xiao H, Xiao L, Griskin NV, White M, Yang XJ, Zhao Y, Mol Cell 2006 23 607 618 10.1016/j.molcel.2006.06.026 16916647 (Pubitemid 44205490)
37. The histone deacetylase inhibitor trichostatin A blocks progesterone receptor-mediated transactivation of the mouse mammary tumor virus promoter in vivo. Wilson MA, Ricci AR, Deroo BJ, Archer TK, J Biol Chem 2002 277 15171 15181 11821430 (Pubitemid 34952596)
38. Moving AHEAD with an international human epigenome project. Jones PA, Archer TK, Baylin SB, Beck S, Berger S, Bernstein BE, Carpten JD, Clark SJ, Costello JF, Doerge RW, Esteller M, Feinberg AP, Gingeras TR, Greally JM, Henikoff S, Herman JG, Jackson-Grusby L, Jenuwein T, Jirtle RL, Kim Y-J, Laird PW, Lim B, Martienssen R, Polyak K, Stunnenberg H, Tlsty TD, Tycko B, Ushijima T, Zhu J, Nature 2008 454 7205 711 715 10.1038/454711a 18685699
39. Polycomb complexes act redundantly to repress genomic repeats and genes. Leeb M, Pasini D, Novatchkova M, Jaritz M, Helin K, Wutz A, Genes Dev 2010 24 265 276 10.1101/gad.544410 20123906
40. Pluripotency-related, valproic acid (VPA)-induced genome-wide histone H3 lysine 9 (H3K9) acetylation patterns in embryonic stem cells. Hezroni H, Sailaja BS, Meshorer E, J Biol Chem 2011 286 35977 35988 10.1074/jbc.M111.266254 21849501
41. Role for Dpy-30 in ES cell-fate specification by regulation of H3K4 methylation within bivalent domains. Jiang H, Shukla A, Wang X, Chen WY, Bernstein BE, Roeder RG, Cell 2011 144 513 525 10.1016/j.cell.2011.01.020 21335234
42. Chromatin signatures of pluripotent cell lines. Azuara V, Perry P, Sauer S, Spivakov M, Jorgensen HF, John RM, Gouti M, Casanova M, Warnes G, Merkenschlager M, Fisher AG, Nat Cell Biol 2006 8 532 538 10.1038/ncb1403 16570078
43. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES, Cell 2006 125 315 326 10.1016/j.cell.2006.02.041 16630819
44. Active genes are tri-methylated at K4 of histone H3. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC, Schreiber SL, Mellor J, Kouzarides T, Nature 2002 419 407 411 10.1038/nature01080 12353038
45. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, Alvarez P, Brockman W, Kim TK, Koche RP, Lee W, Meudenhall E, O'Donovan A, Presser A, Russ C, Xie X, Meissner A, Wernig M, Jaenisch R, Nusbaum C, Lander ES, Bernstein BE, Nature 2007 448 553 560 10.1038/nature06008 17603471 (Pubitemid 47206934)
46. Epigenomic reorganization of the clustered Hox genes in embryonic stem cells induced by retinoic acid. Kashyap V, Gudas LJ, Brenet F, Funk P, Viale A, Scandura JM, J Biol Chem 2011 286 3250 3260 10.1074/jbc.M110.157545 21087926
47. How does noncoding transcription regulate Hox genes? Lempradl A, Ringrose L, Bioessays 2008 30 110 121 10.1002/bies.20704 18200528 (Pubitemid 351196946)
48. Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. Johnson CA, White DA, Lavender JS, O'Neill LP, Turner BM, J Biol Chem 2002 277 9590 9597 10.1074/jbc.M107942200 11777905 (Pubitemid 34953048)
49. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE, Wang C, Brindle PK, Dent SY, Ge K, EMBO J 2011 30 249 262 10.1038/emboj.2010.318 21131905
50. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Pasini D, Malatesta M, Jung HR, Walfridsson J, Willer A, Olsson L, Skotte J, Wutz A, Porse B, Jensen ON, Helin K, Nucleic Acids Res 2010 38 4958 4969 10.1093/nar/gkq244 20385584
51. Histone acetylation and the maintenance of chromatin compaction by Polycomb repressive complexes. Eskeland R, Freyer E, Leeb M, Wutz A, Bickmore WA, Cold Spring Harb Symp Quant Biol 2010 75 71 78 10.1101/sqb.2010.75.053 21502416
52. In vitro generation of lymphoid precursors from embryonic stem cells. Potocnik AJ, Nielsen PJ, Eichmann K, EMBO J 1994 13 5274 5283 7957093 (Pubitemid 24351805)
53. Enhanced expression of alkaline phosphatase in hybrids between neuroblastoma and embryonal carcinoma. Bernstine EG, Koyama H, Ephrussi B, Somatic Cell Genet 1977 3 217 225 10.1007/BF01551816 605381 (Pubitemid 8133602)
54. The promotion of stemness and pluripotency following feeder-free culture of embryonic stem cells on collagen-grafted 3-dimensional nanofibrous scaffold. Hashemi SM, Soudi S, Shabani I, Naderi M, Soleimani M, Biomaterials 2011 32 7363 7374 10.1016/j.biomaterials.2011.06.048 21762983
55. Preparation of site-specific antibodies to acetylated histones. White DA, Belyaev ND, Turner BM, Methods 1999 19 417 424 10.1006/meth.1999.0878 10579937 (Pubitemid 30028601)
56. Immunoprecipitation of native chromatin: NChIP. O'Neill LP, Turner BM, Methods 2003 31 76 82 10.1016/S1046-2023(03)00090-2 12893176 (Pubitemid 36945173)